Where does Astrazeneca AB rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Astrazeneca AB ranks #1,487 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Astrazeneca AB hold?

Astrazeneca AB holds 279 US utility patents granted between 2015 and 2025, spanning 29 technology areas.

What is Astrazeneca AB's Innovation Score?

Astrazeneca AB has an Innovation Score of 52.8 out of 100 (top 10% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Astrazeneca AB's patent grant rate increasing or decreasing?

Astrazeneca AB's recent grant velocity is -26% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Astrazeneca AB's patents?

Astrazeneca AB's patents average 13.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Astrazeneca AB patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Astrazeneca AB

Q: What technology areas does Astrazeneca AB focus on?

Astrazeneca AB's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 246 patents. Grants appear in 29 CPC subclasses total.

USPTO PatentsView assignee record - 279 granted patents across 29 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Astrazeneca ranks #1,487 of 49,997 tracked US assignees by granted-patent volume, with 279 patents across 29 technology areas.

#1,487
of 49,997 US assignees by volume: Top 10%
by Innovation Score (52.8/100): 13.6
avg claims per patent: -26%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R1487 · Foreign Corporation #1,487 · 279 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

GRANTS-MID 279 grants
TOP-DECILE #1,487/49,997
PHOTO-FINISH Bridgestone Sports
CPC-FOCUS A61P · 29 areas
INNOV-PAR 52.8/100
CLAIMS-RICH 13.6 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DOWN -26% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Bridgestone Sports Co., Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Astrazeneca AB · this assignee

53
Bitzer Kühlmaschinen… · near

53
Earlens · near

53
Faurecia Emissions… · near

53
Gree Holdings · near

53
3D Lighting… · lowest

7

What this shows Astrazeneca's Innovation Score is 52.8/100 (top 10% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Astrazeneca's grants concentrate

Astrazeneca AB is a focused PatentsView assignee: 29 CPC subclasses with 88.2% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (39 grants) versus a trough of 17 in 2022. By volume, Astrazeneca sits between Nova Chemicals (International) S.A. and Rensselaer Polytechnic Institute.

Astrazeneca's three-year grant acceleration

From 2019–2021 to 2022–2024, Astrazeneca AB moved from 74 to 68 grants (0.92x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #1,412. See the growth leaderboard.

Nova Chemicals (I…

280
Philip Morris USA

280
Senko Advanced Co…

280
THE Invention Sci…

280
Bridgestone Sports

279
Fireeye

279
Geotab

279
Rensselaer Polyte…

279
Astrazeneca AB ◀

279

What this shows Astrazeneca holds 279 patents at rank #1,487, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Astrazeneca

By rank, the assignees closest to #1,487 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Astrazeneca's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Astrazeneca, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (53 here).

Gree Holdings, Inc. 53 Faurecia Emissions Control Technologies, USA, LLC 53 Bitzer Kühlmaschinenbau GmbH 53 Earlens Corporation 53

Similar claim depth

Nearest assignees by average claims per patent (13.6 here).

Japan Tobacco Inc. 13.6 avg Gogoro, Inc. 13.6 avg Everi Games Inc. 13.6 avg Outotec Oyj 13.6 avg

Astrazeneca's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

53 Top 10% higher than 90% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Astrazeneca AB patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	39	14.0%
2016	25	9.0%
2017	25	9.0%
2018	28	10.0%
2019	32	11.5%
2020	18	6.5%
2021	24	8.6%
2022	17	6.1%
2023	24	8.6%
2024	27	9.7%
2025partial year	20	7.2%

Which technologies does Astrazeneca AB patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 246

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 194

C07D - Heterocyclic Compounds 186

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 27

C07K - Peptides 23

C07C - Acyclic OR Carbocyclic Compounds 15

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 14

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 11

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 10

C08G - Macromolecular Compounds Obtained Otherwise Than BY Reactions Only Involving Unsaturated Carbon-to-carbon Bonds 4

Y02A - Technologies FOR Adaptation TO Climate Change 4

E21B - Earth OR Rock DRILLING; Obtaining OIL, GAS, Water, Soluble OR Meltable Materials OR A Slurry OF Minerals From Wells 4

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 3

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 3

A61J - Containers Specially Adapted FOR Medical OR Pharmaceutical PURPOSES; Devices OR Methods Specially Adapted FOR Bringing Pharmaceutical Products Into Particular Physical OR Administering FORMS; Devices FOR Administering Food OR Medicines ORALLY; Baby COMFORTERS; Devices FOR Receiving Spittle 3

Top 15 of 29 technology areas

Where it ranks

Overall rank by patents

#1,487

of 49,997 tracked assignees

Innovation Score

52.8 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Astrazeneca AB's patent record in context - here's where to go next.

Astrazeneca AB's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 88.2% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #1,487 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Astrazeneca AB against Nova Chemicals (International) S.A., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 52.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.